[300+ Pages Report] The global demand for the cancer gene therapy is expected to increase at a 10.1% CAGR from 2022 to 2032, reaching US$ 2 Billion in 2022. As per Future Market Insights (FMI), the oncolytic virotherapy segment held 49.3% of the overall global cancer gene therapy market in 2021, which is projected to be valued at US$ 5.3 Billion in the year 2032.
| Data Points | Market Insights |
|---|---|
| Cancer Gene Therapy Market Base Year Value (2021) | US$ 1.9 Billion |
| Estimated Market Size (2022) | US$ 2.0 Billion |
| Projected Market Valuation (2032) | US$ 5.3 Billion |
| Value-based CAGR (2022 to 2032) | 10.1% |
| Market Share of Top 5 Countries | 74.8% |
The global market of cancer gene therapy accounted for nearly 45.2% of the overall global gene therapy market worth around US$ 4.0 Billion in 2021.
Initially, gene therapy for monogenetic illnesses was popular; however, gene therapy for cancer treatment is growing in popularity. Cancer gene therapy is a method of treating cancer patients by introducing therapeutic DNA into their bodies.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Demand for cancer gene therapy is forecast to increase at a 10.1% CAGR over the forecast period, in comparison to the 7.1% CAGR registered between 2017 to 2021.
Multiple mutations in a single cell cause cancer to spread. Cancer cells infiltrate new cell, have a rapid metabolism, and are constantly altering shape. Surgery, radiation therapy, and chemotherapy are options for cancer treatment. Gene therapy is utilised if the abovementioned treatments do not deliver the intended results.
In gene therapy, a functional gene, also known as therapeutic DNA, is inserted into the cells of a cancer patient to modify metabolism, alter or repair acquired genetic abnormalities, and impart new functions to cells.
For the last two decades, gene therapy has been a hot topic of research. Ten gene therapy products have been authorized for marketing in at least one country as of January 28, 2018. According to recent forecasts, 12 to 14 new gene therapies will be filed for approval in the following few years, with roughly 40 new medicines approved by the end of 2022.
Oncolytic viral therapy, gene transfer, and gene-induced immunotherapy are examples of cancer treatments. Gene therapy can be used in a variety of ways. For instance, replacing missing or defective genes with healthy genes, altering gene regulation, or introducing foreign genes into cells to alter their function or survival.
Electroporation, magnetofection, naked / plasmid vectors, sonoporation, and gene guns are examples of transgene treatment. Gene-induced immunotherapy is projected to dominate the global cancer gene therapy market over the forecast period.
Various organizations are investing heavily in cancer research. For Instance, in October 2017, American Cancer Society (ACS) approved a US$ 39.8 million funding for 78 training and research grants. These grants were awarded to researchers at 57 institutions across the U.S.
This has brought about significant developments in the field of cancer research and has led to further growth in the global oncogene therapy market.
Governments in various underdeveloped nations are actively taking steps to stimulate various research efforts aimed at producing cancer gene therapy and treatment plans to lower mortality and morbidity rates, which will drive the market.
Because of its high success rate in preclinical and clinical trials, cancer gene therapy is gaining prominence. The most popular method of cancer gene therapy is to replace a cancer-causing mutant gene with a healthy copy of the gene.
Rising success rates of novel medicines and ethical acceptability of gene therapy for cancer treatment will create lucrative opportunities for cancer gene therapy market players. For instance, in August 2017, the US Food and Drug Administration (USFDA) approved an innovative treatment for children suffering from acute lymphoblastic leukemia. This gene therapy, “tisagenlecleucel (Kymriah™)”, is the first to be approved for cancer by the USFDA.
Gene therapy is one of the conceivable treatments suitable to the senior population with low to intermediate risk, according to respondents. In the U.S., cancer gene therapy is widely accepted. As a result, experts have emphasized that cancer gene therapy is deemed safe in the older population, and that the danger associated with gene therapy is minimal.
Principal Consultant
The high costs associated with gene therapy, along with a detrimental immune response are expected to impede the growth in the cancer gene therapy market during the forecast period.
The availability of other cancer treatment types such as chemotherapy and surgery is expected to limit sales. Viruses are the most efficient biological vectors for delivering genes to target cells. Due to safety concerns, non-viral vector delivery systems could be used as a safer alternative.
The shortage of qualified medical professionals for cancer gene therapy in developing countries can hinder the growth of the global cancer gene therapy market.
According to government data and Indian medical association, less than 1,600 oncologists are treating an estimated 1 million cancer patients in the country, with a 20% increase in cancer cases by the end of the decade.
“Rising Awareness Regarding DNA Therapy for Cancer in the U.S. Will Augment Growth”
The U.S. dominated the North America cancer gene therapy market, holding 96.8% of the total market share in 2021, and the trend is expected to continue over the assessment period.
Breast cancer is one of the most frequent diseases in women worldwide, according to the Centers for Disease Control and Prevention (CDC), and it remains the second-largest cause of cancer death in women worldwide, fuelling the expansion of the cancer gene therapy industry. With a high prevalence of cancer in the country, the U.S. market is set to expand at a lucrative rate throughout assessment period.
“Increasing Adoption of Genetic Mutation Lung Cancer Treatment in China Will Boost Sales”
Sales in China are set to account for 32.3% of the East Asia cancer gene therapy market by 2032. The 'Regulations on the Management of Clinical Application of New Biomedical Technologies' and 'Regulations on the Safety Management of Biotechnology Research and Development' have been drafted by China's national health, scientific, and technology agencies.
The purpose of improving the rules and regulations is to create a more reasonable supervisory mechanism, strengthen supervision, increase legal responsibility, and encourage healthy development of biotechnology research, applications, and related businesses. Such developments are expected to bode well for the market over the forecast period.
“Increasing Demand for Gene Targeted Chemotherapy in Germany Will Steer Sales”
Demand in Germany is projected to increase at a CAGR of 11.9% during the forecast period. Manufacturers, healthcare professionals, and patients are hopeful as regulators create a defined path for speedy access to novel cancer gene therapies.
Players, on the other hand, are analysing the new medicines' added benefits. In the realm of gene treatments, major advancements are expected in the forthcoming years, thereby fueling sales in Germany.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
“Demand for Oncolytic Virotherapy Will Gain Traction”
Based on therapy, the oncolytic virotherapy accounted for about 49.3% of the total market share in 2021. Sales in this segment are expected to increase at a 9.5% CAGR over the forecast period.
Oncolytic virus therapy is a promising new therapeutic approach for cancer treatment that has recently been identified. An oncolytic virus is a genetically designed or naturally occurring virus that may selectively reproduce in cancer cells and kill them while causing no harm to normal tissues. Oncolytic virus therapy differs from gene therapy in that it exploits the virus as an active pharmacological reagent rather than just a carrier for transgene delivery.
“Sales of Cancer Gene Therapy for Breast Cancer to Remain High”
In terms of indication, the breast cancer segment held about 24.5% of the total market share in 2021, and is expected to expand at a 9.7% CAGR over the forecast period. Various governments in underdeveloped nations are taking steps to stimulate research efforts aimed at producing cancer gene therapy and treatment plans to lower mortality and morbidity rates, which will drive growth in the cancer gene therapy market over the forecast period.
“Adoption of Cancer Gene Therapy in Hospitals Will Increase”
By service provider, the hospitals segment will expand at a 9.3% CAGR over the assessment period. The presence of trained providers, as well as institutional facilities equipped with treatment options are some factors expected to drive sales in this segment in the forthcoming years.
Moreover, the availability of reimbursement plans for gene therapy will continue pushing sales over the forecast period.
Leading cancer gene therapy manufacturers are focusing on technological advancements in order to increase revenue and expand their footprint in emerging markets through acquisitions, partnerships, and collaborations.
For instance:
| Attributes | Details |
|---|---|
| Estimated Market Size (2022) | US$ 2 Billion |
| Projected Market Valuation (2032) | US$ 5.3 Billion |
| Value-based CAGR (2022 to 2032) | 10.1% |
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2017 to 2021 |
| Market Analysis | US$ Billion for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, Germany, The UK, France, Italy, Spain, Russia, Poland, Georgia China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, GCC Countries, Turkey, and South Africa |
| Key Market Segments Covered | Therapy, Indication, Service Provider, and Region |
| Key Companies Profiled |
|
The global cancer gene therapy market is forecast to reach US$ 2 Bn in 2022 and is set to expand 2.6X over the forecast period.
The cancer gene therapy market is expected to reach US$ 5.3 Bn by end of 2032 at a CAGR of 10.1%
Key trends expected to drive sales in the market include increasing prevalence of cancer, rising awareness about healthcare practices among consumers, and an increase in the adoption of cancer gene therapy.
The key restraints affecting the cancer gene therapy market are the presence of alternatives to cancer gene therapy, the high cost involved in cancer gene therapy, and the shortage of skilled professionals.
North America held the highest market share of 52.8% by value in 2021 in the global cancer gene therapy market.
The U.S., the U.K., Germany, France, and Japan are the top five countries that are expected to drive demand in the cancer gene therapy market.
Merck KGaA, Novartis AG, AstraZeneca Plc. BIOCAD, Crinetics Pharmaceuticals, Inc., EffRx Pharmaceuticals S.A., Euroscreen S.A., Vicore Pharma AB, Amgen, Bristol-Myers Squibb, Cell Genesys Inc., Adaptimmune Therapeutics plc., Achieve Life Science Inc., BioCanCell Ltd., Genelux Corporation, Advantagene Inc., GenVec Inc., GlaxoSmithKline PLC, Amgen Inc. are the key manufacturers in this market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Technology Roadmap 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Technology Assessment 4.2. Disease Epidemiology 4.3. Regulatory Landscape 4.4. Reimbursement Outlook 4.5. Key Marketing & Promotional Strategies Adopted By Companies 4.6. PESTLE Analysis 4.7. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Rise in Healthcare Spending 5.1.3. Global Expenditure on Healthcare Infrastructure 5.2. Forecast Factors - Relevance & Impact 5.2.1. Mergers and Acquisitions 5.2.2. Disease Prevalence and Growth 5.2.3. R&D for Cancer Gene Therapy 5.2.4. Technological Advancements 5.2.5. Regulatory Framework 5.2.6. Reimbursement Policies 5.2.7. Prevalence of Geriatric Age Group 5.2.8. Global Burden of Cancer 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. Revenue By Therapy 6.1.2. Revenue By Indication 6.1.3. Revenue By Service Provider 6.1.4. Revenue By Country 6.2. 2021 Market Scenario 7. Global Market Demand (in Value or Size in US$ Bn) Analysis 2017–2021 and Forecast, 2022–2032 7.1. Historical Market Value (US$ Bn) Analysis, 2017–2021 7.2. Current and Future Market Value (US$ Bn) Projections, 2022–2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2017–2021 and Forecast 2022–2032, By Therapy 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Bn) Trend Analysis, By Therapy, 2017–2021 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Therapy, 2022–2032 8.3.1. Gene Induced Immunotherapy 8.3.2. Oncolytic Virotherapy 8.3.3. Gene Transfer 8.3.4. Others 8.4. Market Attractiveness Analysis By Therapy 9. Global Market Analysis 2017–2021 and Forecast 2022–2032, By Indication 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Bn) Trend Analysis, By Indication, 2017–2021 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Indication, 2022–2032 9.3.1. Breast Cancer 9.3.2. Ovarian Cancer 9.3.3. Liver Cancer 9.3.4. Pancreatic Cancer 9.3.5. Lung Cancer 9.3.6. Prostate Cancer 9.4. Market Attractiveness Analysis By Indication 10. Global Market Analysis 2017–2021 and Forecast 2022–2032, By Service Provider 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Bn) Trend Analysis, By Service Provider, 2017–2021 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Service Provider, 2022–2032 10.3.1. Hospitals 10.3.2. Clinical Research Laboratory 10.3.3. Oncology institutes 10.4. Market Attractiveness Analysis By Service Provider 11. Global Market Analysis 2017–2021 and Forecast 2022–2032, by Region 11.1. Introduction 11.2. Historical Market Size (US$ Bn) Analysis, By Region, 2017–2021 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2022–2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2017–2021 and Forecast 2022–2032 12.1. Introduction 12.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 12.3.1. By Country 12.3.1.1. U.S. 12.3.1.2. Canada 12.3.2. By Therapy 12.3.3. By Indication 12.3.4. By Service Provider 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Therapy 12.4.3. By Indication 12.4.4. By Service Provider 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country Level Analysis & Forecast 12.8.1. U.S. Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Therapy 12.8.1.2.2. By Indication 12.8.1.2.3. By Service Provider 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Therapy 12.8.2.2.2. By Indication 12.8.2.2.3. By Service Provider 13. Latin America Market Analysis 2017–2021 and Forecast 2022–2032 13.1. Introduction 13.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 13.3.1. By Country 13.3.1.1. Mexico 13.3.1.2. Brazil 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Therapy 13.3.3. By Indication 13.3.4. By Service Provider 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Therapy 13.4.3. By Indication 13.4.4. By Service Provider 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. Mexico Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Therapy 13.8.1.2.2. By Indication 13.8.1.2.3. By Service Provider 13.8.2. Brazil Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Therapy 13.8.2.2.2. By Indication 13.8.2.2.3. By Service Provider 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Therapy 13.8.3.2.2. By Indication 13.8.3.2.3. By Service Provider 14. Europe Market Analysis 2017–2021 and Forecast 2022–2032 14.1. Introduction 14.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. U.K. 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Nordic Countries 14.3.1.8. Russia 14.3.1.9. Rest of Europe 14.3.2. By Therapy 14.3.3. By Indication 14.3.4. By Service Provider 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Therapy 14.4.3. By Indication 14.4.4. By Service Provider 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. Germany Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Therapy 14.8.1.2.2. By Indication 14.8.1.2.3. By Service Provider 14.8.2. Italy Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Therapy 14.8.2.2.2. By Indication 14.8.2.2.3. By Service Provider 14.8.3. France Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Therapy 14.8.3.2.2. By Indication 14.8.3.2.3. By Service Provider 14.8.4. U.K. Market Analysis 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Therapy 14.8.4.2.2. By Indication 14.8.4.2.3. By Service Provider 14.8.5. Spain Market Analysis 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Therapy 14.8.5.2.2. By Indication 14.8.5.2.3. By Service Provider 14.8.6. BENELUX Market Analysis 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Therapy 14.8.6.2.2. By Indication 14.8.6.2.3. By Service Provider 14.8.7. Nordic Countries Contact Lenses Market Analysis 14.8.7.1. Introduction 14.8.7.2. Market Analysis and Forecast by Market Taxonomy 14.8.7.2.1. By Therapy 14.8.7.2.2. By Indication 14.8.7.2.3. By Service Provider 14.8.8. Russia Market Analysis 14.8.8.1. Introduction 14.8.8.2. Market Analysis and Forecast by Market Taxonomy 14.8.8.2.1. By Therapy 14.8.8.2.2. By Indication 14.8.8.2.3. By Service Provider 15. East Asia Market Analysis 2017–2021 and Forecast 2022–2032 15.1. Introduction 15.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Therapy 15.3.3. By Indication 15.3.4. By Service Provider 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Therapy 15.4.3. By Indication 15.4.4. By Service Provider 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. China Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Therapy 15.8.1.2.2. By Indication 15.8.1.2.3. By Service Provider 15.8.2. Japan Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Therapy 15.8.2.2.2. By Indication 15.8.2.2.3. By Service Provider 15.8.3. South Korea Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Therapy 15.8.3.2.2. By Indication 15.8.3.2.3. By Service Provider 16. South Asia Market Analysis 2017–2021 and Forecast 2022–2032 16.1. Introduction 16.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Indonesia 16.3.1.3. Malaysia 16.3.1.4. Philippines 16.3.1.5. Thailand 16.3.1.6. Vietnam 16.3.1.7. Rest of South Asia 16.3.2. By Therapy 16.3.3. By Indication 16.3.4. By Service Provider 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Therapy 16.4.3. By Indication 16.4.4. By Service Provider 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. India Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Therapy 16.8.1.2.2. By Indication 16.8.1.2.3. By Service Provider 16.8.2. Indonesia Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Therapy 16.8.2.2.2. By Indication 16.8.2.2.3. By Service Provider 16.8.3. Malaysia Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Therapy 16.8.3.2.2. By Indication 16.8.3.2.3. By Service Provider 16.8.4. Philippines Market Analysis 16.8.4.1. Introduction 16.8.4.2. Market Analysis and Forecast by Market Taxonomy 16.8.4.2.1. By Therapy 16.8.4.2.2. By Indication 16.8.4.2.3. By Service Provider 16.8.5. Thailand Market Analysis 16.8.5.1. Introduction 16.8.5.2. Market Analysis and Forecast by Market Taxonomy 16.8.5.2.1. By Therapy 16.8.5.2.2. By Indication 16.8.5.2.3. By Service Provider 16.8.6. Vietnam Market Analysis 16.8.6.1. Introduction 16.8.6.2. Market Analysis and Forecast by Market Taxonomy 16.8.6.2.1. By Therapy 16.8.6.2.2. By Indication 16.8.6.2.3. By Service Provider 17. Oceania Market 2012-2021 and Forecast 2022-2032 17.1. Introduction 17.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Therapy 17.3.3. By Indication 17.3.4. By Service Provider 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Therapy 17.4.3. By Indication 17.4.4. By Service Provider 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. Australia Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Therapy 17.8.1.2.2. By Indication 17.8.1.2.3. By Service Provider 17.8.2. New Zealand Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Therapy 17.8.2.2.2. By Indication 17.8.2.2.3. By Service Provider 18. Middle East and Africa (MEA) Market Analysis 2017–2021 and Forecast 2022–2032 18.1. Introduction 18.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Israel 18.3.1.3. Turkey 18.3.1.4. South Africa 18.3.1.5. North Africa 18.3.1.6. Rest of Middle East and Africa 18.3.2. By Therapy 18.3.3. By Indication 18.3.4. By Service Provider 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Therapy 18.4.3. By Indication 18.4.4. By Service Provider 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. GCC Countries Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Therapy 18.8.1.2.2. By Indication 18.8.1.2.3. By Service Provider 18.8.2. Israel Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Therapy 18.8.2.2.2. By Indication 18.8.2.2.3. By Service Provider 18.8.3. Turkey Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Therapy 18.8.3.2.2. By Indication 18.8.3.2.3. By Service Provider 18.8.4. South Africa Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Therapy 18.8.4.2.2. By Indication 18.8.4.2.3. By Service Provider 18.8.5. North Africa Market Analysis 18.8.5.1. Introduction 18.8.5.2. Market Analysis and Forecast by Market Taxonomy 18.8.5.2.1. By Therapy 18.8.5.2.2. By Indication 18.8.5.2.3. By Service Provider 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players 19.3. Market Presence Analysis 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Merck KGaA 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Profitability by Market Segments (Product/Channel/Region) 20.3.1.4. Sales Footprint 20.3.1.5. Key Financials 20.3.1.6. SWOT Analysis 20.3.1.7. Strategy Overview 20.3.2. Novartis AG 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Profitability by Market Segments (Product/Channel/Region) 20.3.2.4. Sales Footprint 20.3.2.5. Key Financials 20.3.2.6. SWOT Analysis 20.3.2.7. Strategy Overview 20.3.3. AstraZeneca Plc 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Profitability by Market Segments (Product/Channel/Region) 20.3.3.4. Sales Footprint 20.3.3.5. Key Financials 20.3.3.6. SWOT Analysis 20.3.3.7. Strategy Overview 20.3.4. BIOCAD 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Profitability by Market Segments (Product/Channel/Region) 20.3.4.4. Sales Footprint 20.3.4.5. Key Financials 20.3.4.6. SWOT Analysis 20.3.4.7. Strategy Overview 20.3.5. Crinetics Pharmaceuticals, Inc. 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Profitability by Market Segments (Product/Channel/Region) 20.3.5.4. Sales Footprint 20.3.5.5. Key Financials 20.3.5.6. SWOT Analysis 20.3.5.7. Strategy Overview 20.3.6. EffRx Pharmaceuticals S.A. 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Profitability by Market Segments (Product/Channel/Region) 20.3.6.4. Sales Footprint 20.3.6.5. Key Financials 20.3.6.6. SWOT Analysis 20.3.6.7. Strategy Overview 20.3.7. Euroscreen S.A. 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Profitability by Market Segments (Product/Channel/Region) 20.3.7.4. Sales Footprint 20.3.7.5. Key Financials 20.3.7.6. SWOT Analysis 20.3.7.7. Strategy Overview 20.3.8. Vicore Pharma AB 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Profitability by Market Segments (Product/Channel/Region) 20.3.8.4. Sales Footprint 20.3.8.5. Key Financials 20.3.8.6. SWOT Analysis 20.3.8.7. Strategy Overview 20.3.9. Amgen 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Profitability by Market Segments (Product/Channel/Region) 20.3.9.4. Sales Footprint 20.3.9.5. Key Financials 20.3.9.6. SWOT Analysis 20.3.9.7. Strategy Overview 20.3.10. Bristol-Myers Squibb 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Profitability by Market Segments (Product/Channel/Region) 20.3.10.4. Sales Footprint 20.3.10.5. Key Financials 20.3.10.6. SWOT Analysis 20.3.10.7. Strategy Overview 20.3.11. Cell Genesys Inc. 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Profitability by Market Segments (Product/Channel/Region) 20.3.11.4. Sales Footprint 20.3.11.5. Key Financials 20.3.11.6. SWOT Analysis 20.3.11.7. Strategy Overview 20.3.12. Adaptimmune Therapeutics plc 20.3.12.1. Overview 20.3.12.2. Product Portfolio 20.3.12.3. Profitability by Market Segments (Product/Channel/Region) 20.3.12.4. Sales Footprint 20.3.12.5. Key Financials 20.3.12.6. SWOT Analysis 20.3.12.7. Strategy Overview 20.3.13. Achieve Life Science Inc. 20.3.13.1. Overview 20.3.13.2. Product Portfolio 20.3.13.3. Profitability by Market Segments (Product/Channel/Region) 20.3.13.4. Sales Footprint 20.3.13.5. Key Financials 20.3.13.6. SWOT Analysis 20.3.13.7. Strategy Overview 20.3.14. BioCanCell Ltd. 20.3.14.1. Overview 20.3.14.2. Product Portfolio 20.3.14.3. Profitability by Market Segments (Product/Channel/Region) 20.3.14.4. Sales Footprint 20.3.14.5. Key Financials 20.3.14.6. SWOT Analysis 20.3.14.7. Strategy Overview 20.3.15. Genelux Corporation 20.3.15.1. Overview 20.3.15.2. Product Portfolio 20.3.15.3. Profitability by Market Segments (Product/Channel/Region) 20.3.15.4. Sales Footprint 20.3.15.5. Key Financials 20.3.15.6. SWOT Analysis 20.3.15.7. Strategy Overview 20.3.16. Advantagene Inc., 20.3.16.1. Overview 20.3.16.2. Product Portfolio 20.3.16.3. Profitability by Market Segments (Product/Channel/Region) 20.3.16.4. Sales Footprint 20.3.16.5. Key Financials 20.3.16.6. SWOT Analysis 20.3.16.7. Strategy Overview 20.3.17. GenVec Inc. 20.3.17.1. Overview 20.3.17.2. Product Portfolio 20.3.17.3. Profitability by Market Segments (Product/Channel/Region) 20.3.17.4. Sales Footprint 20.3.17.5. Key Financials 20.3.17.6. SWOT Analysis 20.3.17.7. Strategy Overview 20.3.18. Glaxosmithkline PLC 20.3.18.1. Overview 20.3.18.2. Product Portfolio 20.3.18.3. Profitability by Market Segments (Product/Channel/Region) 20.3.18.4. Sales Footprint 20.3.18.5. Key Financials 20.3.18.6. SWOT Analysis 20.3.18.7. Strategy Overview 20.3.19. Amgen Inc. 20.3.19.1. Overview 20.3.19.2. Product Portfolio 20.3.19.3. Profitability by Market Segments (Product/Channel/Region) 20.3.19.4. Sales Footprint 20.3.19.5. Key Financials 20.3.19.6. SWOT Analysis 20.3.19.7. Strategy Overview 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Cancer Gene Therapy Market
